Literature DB >> 24138045

Stargardt-Fundus flavimaculatus: recent advancements and treatment.

Sara Haji Abdollahi1, Tatsuo Hirose.   

Abstract

Stargardt disease is the most common form of autosomal recessive macular dystrophy. Mutation in the ABCA4 gene (ABCR protein) is responsible for disease manifestation in more than 95% of Stargardt patients. ABCA4 codes for a member of the ATP binding cassette transmembrane protein involved in the transport of all-trans retinal. Dysfunction in this protein causes accumulation of lipofuscin, which is toxic to the RPE and photoreceptors. Presenting symptoms, fundus appearance, and progression of the disease are widely variable in this disease. Different imaging modalities have been utilized to study the presentation and evolution of fundus changes. Although there is ongoing research to better understand the disease process and ways to alternate its path, currently there is no treatment for Startgardt patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24138045     DOI: 10.3109/08820538.2013.825286

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  7 in total

1.  ELLIPSOID ZONE MAPPING AND OUTER RETINAL ASSESSMENT IN STARGARDT DISEASE.

Authors:  Sruthi Arepalli; Elias I Traboulsi; Justis P Ehlers
Journal:  Retina       Date:  2018-07       Impact factor: 4.256

2.  New Insights on the Regulatory Gene Network Disturbed in Central Areolar Choroidal Dystrophy-Beyond Classical Gene Candidates.

Authors:  João Paulo Kazmierczak de Camargo; Giovanna Nazaré de Barros Prezia; Naoye Shiokawa; Mario Teruo Sato; Roberto Rosati; Angelica Beate Winter Boldt
Journal:  Front Genet       Date:  2022-05-17       Impact factor: 4.772

3.  Human Adult Retinal Pigment Epithelial Stem Cell-Derived RPE Monolayers Exhibit Key Physiological Characteristics of Native Tissue.

Authors:  Timothy A Blenkinsop; Janmeet S Saini; Arvydas Maminishkis; Kapil Bharti; Qin Wan; Tina Banzon; Mostafa Lotfi; Janine Davis; Deepti Singh; Lawrence J Rizzolo; Sheldon Miller; Sally Temple; Jeffrey H Stern
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 4.  Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options.

Authors:  Preena Tanna; Rupert W Strauss; Kaoru Fujinami; Michel Michaelides
Journal:  Br J Ophthalmol       Date:  2016-08-04       Impact factor: 4.638

5.  Cross-Sectional and Longitudinal Assessment of Retinal Sensitivity in Patients With Childhood-Onset Stargardt Disease.

Authors:  Preena Tanna; Michalis Georgiou; Jonathan Aboshiha; Rupert W Strauss; Neruban Kumaran; Angelos Kalitzeos; Richard G Weleber; Michel Michaelides
Journal:  Transl Vis Sci Technol       Date:  2018-11-27       Impact factor: 3.283

6.  Cross-Sectional and Longitudinal Assessment of the Ellipsoid Zone in Childhood-Onset Stargardt Disease.

Authors:  Preena Tanna; Michalis Georgiou; Rupert W Strauss; Naser Ali; Neruban Kumaran; Angelos Kalitzeos; Kaoru Fujinami; Michel Michaelides
Journal:  Transl Vis Sci Technol       Date:  2019-03-01       Impact factor: 3.283

7.  Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry.

Authors:  Michalis Georgiou; Thomas Kane; Preena Tanna; Zaina Bouzia; Navjit Singh; Angelos Kalitzeos; Rupert W Strauss; Kaoru Fujinami; Michel Michaelides
Journal:  Am J Ophthalmol       Date:  2019-12-06       Impact factor: 5.258

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.